This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

blinatumomab (Blincyto®)

Reference No. 3769

Publication date:

Appraisal information

blinatumomab (Blincyto®) 38.5 micrograms powder for concentrate and solution for solution for infusion

Company: Amgen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 06/03/2019
AWMSG meeting date: 10/04/2019
Submission Type: Limited Submission
Status: Recommended
Advice No: 0519
Ratification by Welsh Government: 12/04/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

Blinatumomab (Blincyto®) is recommended as an option for use within NHS Wales as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive Bcell precursor acute lymphoblastic leukaemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)